TG Therapeutics, Inc. (LON:0VGI)
London flag London · Delayed Price · Currency is GBP · Price in USD
37.50
-1.05 (-2.72%)
At close: Mar 14, 2025

TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of GBP 3.83 billion. The enterprise value is 3.81 billion.

Market Cap 3.83B
Enterprise Value 3.81B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date Aug 4, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class 145.23M
Shares Outstanding n/a
Shares Change (YoY) +9.66%
Shares Change (QoQ) +1.58%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 135.08M

Valuation Ratios

The trailing PE ratio is 126.36 and the forward PE ratio is 25.06.

PE Ratio 126.36
Forward PE 25.06
PS Ratio 12.80
PB Ratio 20.85
P/TBV Ratio 20.85
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 83.32, with an EV/FCF ratio of -80.63.

EV / Earnings 125.83
EV / Sales 13.38
EV / EBITDA 83.32
EV / EBIT 86.45
EV / FCF -80.63

Financial Position

The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.07.

Current Ratio 4.02
Quick Ratio 2.91
Debt / Equity 1.07
Debt / EBITDA 4.10
Debt / FCF -4.17
Interest Coverage 2.10

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 9.79%.

Return on Equity (ROE) 19.70%
Return on Assets (ROA) 7.26%
Return on Invested Capital (ROIC) 9.79%
Return on Capital Employed (ROCE) 12.05%
Revenue Per Employee 849,599
Profits Per Employee 86,084
Employee Count 338
Asset Turnover 0.75
Inventory Turnover 0.41

Taxes

In the past 12 months, TG Therapeutics has paid 2.00 million in taxes.

Income Tax 2.00M
Effective Tax Rate 6.21%

Stock Price Statistics

The stock price has increased by +138.40% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change +138.40%
50-Day Moving Average 32.07
200-Day Moving Average 23.65
Relative Strength Index (RSI) 66.40
Average Volume (20 Days) 3,606

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 10.18

Income Statement

In the last 12 months, TG Therapeutics had revenue of GBP 299.06 million and earned 30.30 million in profits. Earnings per share was 0.18.

Revenue 299.06M
Gross Profit 261.45M
Operating Income 46.30M
Pretax Income 32.31M
Net Income 30.30M
EBITDA 46.34M
EBIT 46.30M
Earnings Per Share (EPS) 0.18
Full Income Statement

Balance Sheet

The company has 213.81 million in cash and 197.04 million in debt, giving a net cash position of 16.76 million.

Cash & Cash Equivalents 213.81M
Total Debt 197.04M
Net Cash 16.76M
Net Cash Per Share n/a
Equity (Book Value) 183.66M
Book Value Per Share 1.26
Working Capital 374.84M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -47.23 million and capital expenditures -54,179, giving a free cash flow of -47.29 million.

Operating Cash Flow -47.23M
Capital Expenditures -54,179
Free Cash Flow -47.29M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 87.43%, with operating and profit margins of 15.48% and 10.13%.

Gross Margin 87.43%
Operating Margin 15.48%
Pretax Margin 10.80%
Profit Margin 10.13%
EBITDA Margin 15.49%
EBIT Margin 15.48%
FCF Margin n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -9.66%
Shareholder Yield n/a
Earnings Yield 0.79%
FCF Yield -1.24%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

TG Therapeutics has an Altman Z-Score of 3.66 and a Piotroski F-Score of 3.

Altman Z-Score 3.66
Piotroski F-Score 3